Fibroblast growth factor 21 regulates foam cells formation and inflammatory response in Ox-LDL-induced THP-1 macrophages

Wang, Nan; Li, Junyan; Li, Shuai; Guo, Xiaochen; Wu, Tong; Wang, Wenfei; Li, Deshan

doi:10.1016/j.biopha.2018.09.143

Cited by 41 publications

(36 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…515 FGF21 inhibits macrophage migration and significantly reduces inflammatory factor expression in oxidized low-density lipoprotein-induced THP-1 macrophages. 516 In addition, FGF21 can also repress inflammatory factors induced by insulin resistance. 517 FGF21 has anti-inflammatory effect on preadipocytes via FRS2/ ERK1/2 signaling pathway.…”

Section: Fgf Signaling In Inflammatory Responsementioning

confidence: 99%

FGF/FGFR signaling in health and disease

Xie

Yang

et al. 2020

Sig Transduct Target Ther

454

391

View full text Add to dashboard Cite

Growing evidences suggest that the fibroblast growth factor/FGF receptor (FGF/FGFR) signaling has crucial roles in a multitude of processes during embryonic development and adult homeostasis by regulating cellular lineage commitment, differentiation, proliferation, and apoptosis of various types of cells. In this review, we provide a comprehensive overview of the current understanding of FGF signaling and its roles in organ development, injury repair, and the pathophysiology of spectrum of diseases, which is a consequence of FGF signaling dysregulation, including cancers and chronic kidney disease (CKD). In this context, the agonists and antagonists for FGF-FGFRs might have therapeutic benefits in multiple systems.

show abstract

Section: Fgf Signaling In Inflammatory Responsementioning

confidence: 99%

FGF/FGFR signaling in health and disease

Xie

Yang

et al. 2020

Sig Transduct Target Ther

454

391

View full text Add to dashboard Cite

show abstract

“…It is a secreted protein that acts mainly as an important endocrine metabolism regulator by inducing weight loss and controlling insulin signalling and glucose and lipid metabolism [ 316 ]. It was also described to have a well-characterised anti-inflammatory effect on different tissues/cells, including obese adipose tissue [ 320 , 321 ], liver [ 322 ], pancreas [ 323 ], lungs [ 324 ], heart [ 325 ], skeletal muscle [ 326 ], and macrophages [ 327 , 328 ].…”

Section: Role Of Some Adipokines In Inflammatory Processes Associamentioning

confidence: 99%

Adipokines and Inflammation: Focus on Cardiovascular Diseases

Feijóo‐Bandín

Aragón-Herrera

Moraña-Fernández

et al. 2020

IJMS

View full text Add to dashboard Cite

It is well established that adipose tissue, apart from its energy storage function, acts as an endocrine organ that produces and secretes a number of bioactive substances, including hormones commonly known as adipokines. Obesity is a major risk factor for the development of cardiovascular diseases, mainly due to a low grade of inflammation and the excessive fat accumulation produced in this state. The adipose tissue dysfunction in obesity leads to an aberrant release of adipokines, some of them with direct cardiovascular and inflammatory regulatory functions. Inflammation is a common link between obesity and cardiovascular diseases, so this review will summarise the role of the main adipokines implicated in the regulation of the inflammatory processes occurring under the scenario of cardiovascular diseases.

show abstract

“…153,158 Indeed, preliminary in vitro evidence suggests that FGF21 regulates cholesterol efflux, oxLDL uptake, and foam cell formation in THP1 macrophages and inhibits macrophages' inflammatory capacity through the Nrf2 pathway (Figure 3). [159][160][161] Moreover, recent data from diet-induced obesity and adaptive thermogenesis models indicate that FGF21 promotes anti-inflammatory macrophage polarization in adipose depots and white adipose tissue browning, which could effectively prevent adipose tissue from adopting pro-inflammatory profiles. [162][163][164] In context of cardiovascular health and disease, agonizing FGF21 pathways might be advantageous because the adipose tissue is an active endocrine organ that can favor cardiovascular disease progression by inducing chronic, low-grade inflammation via hormones and proinflammatory mediators (i.e.…”

Section: Fibroblast Growth Factor 21mentioning

confidence: 99%

“…• Attenuates plaque formation and macrophage accumulation in part by inhibiting liver cholesterol biosynthesis in atherosclerosis [153] • Inhibits smooth muscle cell proliferation in atherosclerosis [153] • Prevents foam cell formation by increasesing cholesterol efflux and reducing expression of inflammatory mediators in vitro [159][160][161] • Counteracts AngII-induced hypertension and vascular inflammation by inducing ACE2 in adipocytes and renal cells [158] • Attenuates cardiac remodeling and promotes repair by promoting cardiomyocyte survival after Mi [154,157] • Ameliorates cardiac fibrosis, hypertrophy, oxidative stress, and inflammation in part via signaling in cardiomyocytes in diabetic cardiomyopathy [156] • Role in atherosclerosis, MI, and other types of CVD requires further study, especially with respect to FGF21 effects on leukocytes and the activities of specific Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2020 July 01.…”

Section: Protectivementioning

confidence: 99%

Growth Factors as Immunotherapeutic Targets in Cardiovascular Disease

Mindur

Świrski

2019

ATVB

View full text Add to dashboard Cite

Growth factors, such as colony-stimulating factors (CSFs), epidermal growth factors (EGFs), and fibroblast growth factors (FGFs) are signaling proteins that control a wide range of cellular functions. Although growth factor networks are critical for intercellular communication and tissue homeostasis, their abnormal production or regulation occurs in various pathologies. Clinical strategies that target growth factors or their receptors are used to treat a variety of conditions, but have yet to be adopted for cardiovascular disease. In this review, we focus on M-CSF, GM-CSF, IL-3, EGFR, and FGF21. We first discuss the efficacy of targeting these growth factors in other disease contexts (i.e. inflammatory/autoimmune diseases, cancer, or metabolic disorders) and then consider arguments for or against targeting them to treat cardiovascular disease.

show abstract

Fibroblast growth factor 21 regulates foam cells formation and inflammatory response in Ox-LDL-induced THP-1 macrophages

Cited by 41 publications

References 38 publications

FGF/FGFR signaling in health and disease

FGF/FGFR signaling in health and disease

Adipokines and Inflammation: Focus on Cardiovascular Diseases

Growth Factors as Immunotherapeutic Targets in Cardiovascular Disease

Contact Info

Product

Resources

About